Stability of the hybrid epithelial/mesenchymal phenotype MK Jolly, SC Tripathi, D Jia, SM Mooney, M Celiktas, SM Hanash, ... Oncotarget 7 (19), 27067, 2016 | 396 | 2016 |
Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival MJ Schliekelman, A Taguchi, J Zhu, X Dai, J Rodriguez, M Celiktas, ... Cancer research 75 (9), 1789-1800, 2015 | 216 | 2015 |
Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome SC Tripathi, HL Peters, A Taguchi, H Katayama, H Wang, A Momin, ... Proceedings of the National Academy of Sciences 113 (11), E1555-E1564, 2016 | 188 | 2016 |
Metastatic progression of prostate cancer and e-cadherin: Regulation by Zeb1 and Src family kinases AP Putzke, AP Ventura, AM Bailey, C Akture, J Opoku-Ansah, M Çeliktaş, ... The American journal of pathology 179 (1), 400-410, 2011 | 168 | 2011 |
MCAM mediates chemoresistance in small-cell lung cancer via the PI3K/AKT/SOX2 signaling pathway SC Tripathi, JF Fahrmann, M Celiktas, M Aguilar, KD Marini, MK Jolly, ... Cancer research 77 (16), 4414-4425, 2017 | 104 | 2017 |
Role of CPS1 in cell growth, metabolism, and prognosis in LKB1-inactivated lung adenocarcinoma M Çeliktaş, I Tanaka, S Chandra Tripathi, JF Fahrmann, ... Journal of the National Cancer Institute 109 (3), djw231, 2017 | 89 | 2017 |
Distinguishing mechanisms underlying EMT tristability D Jia, MK Jolly, SC Tripathi, P Den Hollander, B Huang, M Lu, M Celiktas, ... Cancer convergence 1, 1-19, 2017 | 82 | 2017 |
A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets A Taguchi, AD Taylor, J Rodriguez, M Çeliktaş, H Liu, X Ma, Q Zhang, ... Cancer research 74 (17), 4694-4705, 2014 | 48 | 2014 |
Proteomic signatures associated with p53 mutational status in lung adenocarcinoma A Taguchi, O Delgado, M Çeliktaş, H Katayama, H Wang, AF Gazdar, ... Proteomics 14 (23-24), 2750-2759, 2014 | 29 | 2014 |
SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1–Negative Lung Adenocarcinomas I Tanaka, D Dayde, MC Tai, H Mori, LM Solis, SC Tripathi, JF Fahrmann, ... JNCI: Journal of the National Cancer Institute 114 (2), 290-301, 2022 | 23 | 2022 |
Mutational activation of the NRF2 pathway upregulates kynureninase resulting in tumor immunosuppression and poor outcome in lung adenocarcinoma JF Fahrmann, I Tanaka, E Irajizad, X Mao, JB Dennison, E Murage, ... Cancers 14 (10), 2543, 2022 | 21 | 2022 |
CES2 Expression in pancreatic adenocarcinoma is predictive of response to irinotecan and is associated with type 2 diabetes M Capello, JF Fahrmann, MV Rios Perez, JV Vykoukal, E Irajizad, ... JCO Precision Oncology 4, 426-436, 2020 | 14 | 2020 |
Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget 7, 27067–27084 MK Jolly, SC Tripathi, D Jia, SM Mooney, M Celiktas, SM Hanash, ... | 13 | 2016 |
Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget. 2016; 7: 27067–84 MK Jolly, SC Tripathi, D Jia, SM Mooney, M Celiktas, SM Hanash, ... | 10 | |
Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget. 2016; 7 (19): 27067–84 MK Jolly, SC Tripathi, D Jia, SM Mooney, M Celiktas, SM Hanash, ... PubMed Abstract| Publisher Full Text| Free Full Text| F1000 Recommendation, 0 | 9 | |
A novel MTA non-competitive PRMT5 inhibitor R Malik, PK Park, CM Barbieri, Y Blat, S Sheriff, CA Weigelt, LM Kopcho, ... Cancer Research 81 (13_Supplement), 1140-1140, 2021 | 5 | 2021 |
Stability of the hybrid epithelial/mesenchymal phenotype, Oncotarget (2016) MK Jolly, SC Tripathi, D Jia, SM Mooney, M Celiktas, SM Hanash | 5 | |
Distinguishing mechanisms underlying EMT tristability. Cancer Converg. 2017 D Jia, MK Jolly, SC Tripathi, P Den Hollander, B Huang, M Lu, M Celiktas | 5 | |
Stability and stemness of the hybrid epithelial-mesenchymal phenotype MK Jolly, D Jia, SC Tripathi, S Mooney, M Celiktas, SM Hanash, SA Mani, ... Cancer Research 77 (13_Supplement), 3053-3053, 2017 | 1 | 2017 |
Loss of immunoproteasome driven by EMT is associated with immune evasion and poor prognosis in non-small cell lung cancer SC Tripathi, HL Peters, A Taguchi, H Katayama, H Wang, A Momin, ... Journal of Thoracic Oncology 11 (2), S48-S49, 2016 | 1 | 2016 |